Efficacy and safety of avapritinib in previously treated patients with advanced systemic mastocytosis

Advanced systemic mastocytosis (AdvSM) is a rare myeloid neoplasm, driven by the KIT D816V mutation in >90% of patients. Avapritinib, a potent, highly selective D816V-mutant KIT inhibitor, is approved for treatment of adults with AdvSM by the US Food and Drug Administration, regardless of prior t...

Descripción completa

Detalles Bibliográficos
Autores principales: Reiter, Andreas, Schwaab, Juliana, DeAngelo, Daniel J., Gotlib, Jason, Deininger, Michael W., Pettit, Kristen M., Alvarez-Twose, Iván, Vannucchi, Alessandro M., Panse, Jens, Platzbecker, Uwe, Hermine, Olivier, Dybedal, Ingunn, Lin, Hui-Min, Rylova, Svetlana N., Ehlert, Katrin, Dimitrijević, Saša, Radia, Deepti H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2022
Materias:
Regular Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9647833/
https://www.ncbi.nlm.nih.gov/pubmed/35640224
http://dx.doi.org/10.1182/bloodadvances.2022007539

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9647833/
https://www.ncbi.nlm.nih.gov/pubmed/35640224
http://dx.doi.org/10.1182/bloodadvances.2022007539

Ejemplares similares